Status:
WITHDRAWN
Stem Cell Study for Patients With Heart Failure
Lead Sponsor:
Losordo, Douglas, M.D.
Conditions:
Myocardial Ischemia
Congestive Heart Failure
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will impr...
Eligibility Criteria
Inclusion
- Subjects greater than 21 years old.
- Subjects with functional class (NYHA) III ischemic heart failure.
- Subjects who have attempted "best" cardiac medical therapy including long-acting nitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-converting enzyme inhibitors without control of symptoms.
- Subjects must be identified as non-candidates for conventional revascularization by their referring cardiologist. The patient's angiogram will then be reviewed by an independent interventional cardiologist and independent cardiac surgeon to determine if the patient is eligible for revascularization.
- Subjects must have left ventricular ejection fraction \<40% by echocardiography.
- All subjects must have a recent coronary angiogram (within the last 1 year) to document the coronary anatomy and insure the presence of coronary disease that is not amenable to standard revascularization procedures.
- Have serum B-type Natriuretic Peptide (BNP) level \>100 pg/ml.
Exclusion
- Myocardial infarction (Q wave or non-Q wave defined as CKMB \>3 times normal) within 30 days of treatment.
- Successful coronary revascularization procedures within 3 months of study enrollment.
- Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment.
- NYHA Class I, II or IV heart failure and patients with idiopathic or non-ischemic heart failure.
- History of severe aortic stenosis (aortic valve area \< 1.0 cm2) or insufficiency (\>2+); severe mitral stenosis (mitral valve area \<1.5 cm2); or severe mitral insufficiency(\>2+).
- Implantation of biventricular pacemaker within 90 days of study treatment.
- Severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary disease, renal failure or cancer).
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00346177
Start Date
September 1 2010
End Date
September 1 2012
Last Update
September 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611